Clinical and virologic response to episodic acyclovir for genital ulcers among HIV-1 seronegative, herpes simplex virus type 2 seropositive African women: a randomized, placebo-controlled trial

Sex Transm Dis. 2012 Jan;39(1):21-4. doi: 10.1097/OLQ.0b013e31823b50c6.

Abstract

In a randomized trial among African women with recurrent genital herpes, episodic acyclovir therapy resulted in modestly greater likelihood of lesion healing (hazard ratio [HR] = 1.48, P = 0.098; mean, 5.1 vs. 6.0 days) and cessation of herpes simplex virus shedding (HR = 1.88, P = 0.008; mean, 3.0 vs. 5.0 days) compared with placebo, similar to results of studies in high-income countries (ClinicalTrials.gov registration NCT00808405).

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Acyclovir / therapeutic use*
  • Adult
  • Antiviral Agents / therapeutic use*
  • DNA, Viral / genetics
  • Double-Blind Method
  • Female
  • HIV Seronegativity
  • HIV-1 / immunology
  • HIV-1 / isolation & purification
  • Herpes Genitalis / drug therapy*
  • Herpes Genitalis / genetics
  • Herpes Genitalis / virology
  • Herpesvirus 2, Human / drug effects
  • Herpesvirus 2, Human / immunology*
  • Herpesvirus 2, Human / isolation & purification
  • Humans
  • Kaplan-Meier Estimate
  • Middle Aged
  • Recurrence
  • Seroepidemiologic Studies
  • South Africa / epidemiology
  • Ulcer / drug therapy*
  • Ulcer / genetics
  • Ulcer / virology
  • Virus Shedding / drug effects
  • Zambia / epidemiology

Substances

  • Antiviral Agents
  • DNA, Viral
  • Acyclovir

Associated data

  • ClinicalTrials.gov/NCT00808405